Company Overview of Raven Biotechnologies, Inc.
As of July 17, 2008 Raven Biotechnologies, Inc. was acquired by MacroGenics, Inc. Raven Biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. Raven Biotechnologies, Inc. was founded in 1999 and is based in South San Francisco, California.
One Corporate Drive
South San Francisco, CA 94080
Founded in 1999
Key Executives for Raven Biotechnologies, Inc.
Raven Biotechnologies, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
|3D Biomatrix Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Raven Biotechnologies, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.